Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Actuate Therapeutics IncNASDAQ: ACTU
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 109.1% from a year ago
Cash & equivalents stood at $8.13M at the end of Q1 FY2026, up 109.1% from a year earlier and down 38.2% from the prior quarter. Over 3 fiscal years it compounded at -13.7% a year.
Context
- Cash & equivalents amounted to 91.3% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +109.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 13.16M USD
- Year-over-year change
- +52.3%
- 3-year CAGR
- -13.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.16M | +52.3% |
| FY2024 | 2024-12-31 | 8.64M | +192.1% |
| FY2023 | 2023-12-31 | 2.96M | -85.5% |
| FY2022 | 2022-12-31 | 20.45M | — |
Cash & Equivalents vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +109.1% is the 2nd highest of 9, against a peer median of -3.4%.
- Cash & equivalents amounts to 91.3% of total assets for ACTU, versus a peer median of 32.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $169.87M USD | +239.4% | +90.1% | 33.5% | |
| Mar 2026 | CHF 78.53M CHF | -3.5% | -2.0% | 89.9% | |
| Mar 2026 | $76.96M USD | +102.7% | -24.7% | 32.1% | |
| Mar 2026 | $56.13M USD | +14.8% | -28.3% | 95.1% | |
| Mar 2026 | $42.15M USD | -3.4% | -30.7% | 27.0% | |
| Mar 2026 | $29.83M USD | -49.3% | -34.5% | 25.4% | |
| Mar 2026 | $27.36M USD | -48.0% | +1.9% | 7.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $14.95M USD | -18.5% | +33.5% | 65.9% |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.13M USD | +109.1% | -13.7% | 91.3% |
| Peer median (excluding ACTU) | — | -3.4% | -13.4% | 32.8% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.